Our experts have written, co-written, and provided insights into hundreds of publications.
Asseburg C, Mankinen P, Soini E. CO131 Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients in Finland (FINPAH) – A Descriptive Retrospective Real World Cohort Study Between 2008 and 2020.
Asseburg C, Mankinen P, Soini E. (737) Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Finland Between 2008 and 2020 (FINPAH) - A Descriptive Real-World Cohort Study.
Asseburg C, Oksanen M, Soini E. Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study.
Asseburg C, Oksanen M, Soini E. Treatment Patterns for Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Finland Between 2008 and 2020 - A Descriptive Real-World Cohort Study (FINPAH).
Zhu D, Karki S, Dhariwal M, Soini E, Asseburg C. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A Meta-Analysis. Ophthalmol Ther 2024. https://doi.org/10.1007/s40123-024-01085-9
Pentikäinen M, Simonen P, Tuunanen H, Pauliina P, Harju T, Jääskeläinen P, Asseburg C, Oksanen M, Soini E, Wennerström C, Puhakka A, FINPAH study group. Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH). JHLT Open 2024;7.
Väätäinen S, Ehlers P, Tamminen N, Soini E. Direct and Indirect Benefits of Clinical Trials for the Public Health Care: Finnish Society Gains 10 Million Euros of Value Per Trial. Value Health 2024;27:S2.
Haikonen-Salo L, Jalkanen K, Väätäinen S, Mankinen P, Soini E. Finnish Society Gains 2.6 Billion Euros of Value Annually From the Pharmaceutical Work Provided by the Licensed Community Pharmacies. Value Health 2024;27:S2.
Soini E. Who Are the Champions in Our Ecosystems – Deep Dive to Data & Digital Work of Ecosystems in the Global ECAlliance Network. 6th Digital Health Society Summit 2024.
Väätäinen S, Soini E. Integrating Architecture Methodology into Health Technology Assessments and Pharmacoeconomic Evaluations. Farmasian päivät 2024.
Soini E, Väätäinen S. Comparison of SPESiOR and Other Secure Processing Environment (SPE) -type Environments from Finnish, Nordic, European, and Global Settings. Farmasian päivät 2024.
Väätäinen S, Ehlers P, Tamminen N, Soini E. The Benefits of Conducting Clinical Drug Trials in the Finnish Public Health Care: The Society Gains 10 Million Euros of Value per Trial. Farmasian päivät 2024.
Haikonen-Salo L, Jalkanen K, Väätäinen S, Mankinen P, Soini E. Pharmaceutical Work Provided by the Finnish Community Pharmacies Results to Significant Cost Savings and Value for Society. Farmasian päivät 2024.
Soini E. Laaturekistereiden käyttö vaikuttavamman soten tuottamisessa. Hyvinvointialueet ja lääkehoito 2024. Pharmaca.
Martikainen J. Sydän- ja verisuonisairaudet ovat Suomessa merkittävä huolenaihe. MTV3 Huomenta Suomi 2024.
Soini E. Cost-Effectiveness of Prevention: Alzheimer’s Disease and Hereditary Breast and Ovarian Cancer. Kuopio Health Insights 2024 – KHI2024 – Pharma Development & Digital Health: 13–14.8.2024.
Soini E. Welcome and Kuopio Health introduction. Kuopio Health Insights 2024 – KHI2024 – Pharma Development & Digital Health: 13–14.8.2024.
Apteekkien farmaseuttisen työn arvo. ESiOR Oy:n raportti 6.8.2024. Suomen Apteekkariliitto.
Oksanen M, Parviainen J, Asseburg C, Hageman S, Rissanen TT, Kivelä A, Taipale K, Visseren F, Martikainen J. Risk-Stratified Analysis of Long-Term Clinical Outcomes and Cumulative Costs in Finnish Patients with Recent Acute Coronary Syndrome or Coronary Revascularisation: A 5-Year Real-World Study Using Electronic Health Records. Eur Heart J Open 2024;
Soini E. AI and Machine Learning in HEOR. Value Health 2024;27:S1.
Soini E, Asseburg C, Jalkanen K, Pehrsson M, Lundström T, Meretoja T, Hautalahti M, Salminen E, Auranen A, Mäkelä J, Carpén O. Lifetime Cost-Effectiveness of Hereditary Breast and Ovarian Cancer Prevention Based on FinnGen and Biobank Data, Data Returning Process, and Prophylaxis. Value Health 2024;27:S1.
Haikonen-Salo L, Jalkanen K, Ihalainen J, Forsberg MM, Soini E. Predictive Cost-Effectiveness Evaluation of Using a Machine Learning-Based Alzheimer’s Disease Risk Prediction Tool for Users of Social and Health Services Aged over 65 in Finland. Value Health 2024;27:S1.
Soini E. European Health Data Space (EHDS) Requires Secure Processing Environments (SPEs) – Comparison of SPESiOR to Other SPE-Type Environments from Finnish, Nordic, European, and Global Settings. Value Health 2024;27:S1.
Soini E. AI x Pharma x RWE 2024. Pharmaca.
Miten yhteiskunta hyötyy Suomessa tehtävistä lääketutkimuksista? Lääketutkimuksen arvo yhteiskunnalle. Loppuraportti 11.6.2024, ESiOR Oy. Saatavilla: https://www.laaketeollisuus.fi/media/julkaisut/esitteita-ja-raportteja/240611-ltlt1-esior-laaketutkimuksen-yhteiskunnallinen-arvo-loppuraportti-11.6.2024.pdf Lisätiedot: Erkki Soini
Hallinen T, Tuovinen M, Niskanen L. Empagliflotsiinin kustannusvaikuttavuus sitagliptiiniin verrattuna tyypin 2 diabeteksen hoidossa Suomessa. Dosis 2024;40(1): 46–67.
Soini E. Potilastiedoista vaikuttavuuteen. Webinaari 15.2.2024: Rekisteritutkimukset: Terveydenhuollon virstanpylväitä. Pharmaca Health Intelligence.
Soini E. Vaikuttavuus hankinnoissa -verkkokoulutus, 2023. MedLoop Osaamiskeskus, Sailab – MedTech Finland ry.
Soini E. Vaikuttavuus hankintakriteerinä. Valtakunnallinen terveydenhuollon hankintaseminaari 6.10.2022 Pikku-Finlandia, Sailab – MedTech Finland ry.
Catalogue of EHDS services for secondary use of health data. Milestone M7.5, 9th December 2021. TEHDAS - Joint Action Towards European Health Data Space. Co-author: Soini, E.